Regulus Therapeutics
RGLS
#7340
Rank
โ‚น54.64 B
Marketcap
โ‚น789.32
Share price
0.00%
Change (1 day)
485.06%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.47 Billion a decrease over its 2023 earnings that were of -โ‚น2.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-10.23%
2024 -โ‚น4.47 Billion56.97%
2023 -โ‚น2.85 Billion6.51%
2022 -โ‚น2.68 Billion2.53%
2021 -โ‚น2.61 Billion93.59%
2020 -โ‚น1.35 Billion-15.41%
2019 -โ‚น1.6 Billion-64.46%
2018 -โ‚น4.48 Billion-33.26%
2017 -โ‚น6.72 Billion-13.98%
2016 -โ‚น7.81 Billion44.77%
2015 -โ‚น5.39 Billion-1.63%
2014 -โ‚น5.48 Billion203.6%
2013 -โ‚น1.81 Billion8.65%
2012 -โ‚น1.67 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น692.61 B-15,196.86%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น97.83 B-2,232.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น1.152 T-25,211.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.386 T-30,317.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น763.15 B-16,734.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น10.68 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น11.39 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น108.78 B-2,471.21%๐Ÿ‡บ๐Ÿ‡ธ USA